Skip to main content
European Commission logo print header

Efficacy of Leveraging Endocrine Therapies for Renoprotection during Intensive Care

Project description

Protecting kidney function in intensive care

Acute kidney injury (AKI) is defined as the deterioration of renal function in a rather short period of time and is a highly prevalent complication among patients hospitalised in the intensive care unit (ICU). The working hypothesis of the EU-funded ELECTRIC project is that prevention of AKI in ICU patients necessitates protection of renal function. Researchers will therefore employ an animal model to test two new agents used to protect patients with diabetes from chronic kidney disease. They will measure biomarkers associated with renal function and develop innovative techniques that allow the non-invasive measurement of renal physiology in patients.


On the intensive care unit, more than 50% of patients have acute kidney injury, and these patients suffer higher mortality and long-term morbidity. To date, no specific therapies exist to prevent or treat acute kidney injury on the intensive care unit. We now have two new endocrinologic agents, glucagon-like peptide-1 receptor agonists and sodium-glucose transport protein 2 inhibitors, able to protect patients with diabetes from chronic kidney disease. The objective of this action is to investigate whether the renoprotective mechanisms of these agents can reduce markers of acute kidney injury in patients on the intensive care unit. This action incorporates a highly sophisticated animal model for the essential invasive measurement of renal physiology. To translate these findings to the clinical situation, I will employ new and innovative measurement techniques such as urinary oxygenation, new kidney biomarkers and advanced renal imaging techniques to elucidate these renoprotective mechanisms in humans. The involved universities of Amsterdam and the University of Melbourne bring together world leading experts on acute kidney injury, endocrinologic therapies, and intensive care medicine. By connecting their expertise, this action will not only provide insight into the renoprotective properties of the studied interventions and so improve the outcome of patients, but also train me as a researcher able to improve renal outcomes beyond the scope of this action.



Net EU contribution
€ 277 259,52
Meibergdreef 15
1105AZ Amsterdam

See on map

West-Nederland Noord-Holland Groot-Amsterdam
Activity type
Higher or Secondary Education Establishments
Other funding
€ 0,00

Partners (1)